It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

24 Keywords: COVID-19; serology; proteomics; inflammation; cellular immunity.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

Abbreviations

- ADE, antibody-dependent enhancement; ARDS, acute respiratory distress syndrome; C1,
- complement 1; CLIA, chemiluminescence immunoassay; COVID-19, Coronavirus Disease 2019;
- CV, coefficient of variation; DDA, data-dependent acquisition; DEP, differentially expressed
- protein; EHR, electronic hospital record; HDL-C, high-density lipoprotein cholesterol; IQR,
- interquartile range; LDL-C, low-density lipoprotein cholesterol; LOESS, locally weighted
- scatterplot smoothing NAb, neutralizing antibody; nonVac, non-vaccinated; PCA, principal
- component analysis; R1, one-year revisit; R2, two-year revisit; RBD, receptor binding domain;
- RLU, relative luminescence unit; RT-PCR, reverse-transcriptase polymerase-chain-reaction; TC,
- total cholesterol; TEAB, triethylammonium bicarbonate; TG, triglyceride; TMT, tandem mass tag;
- Vac, vaccinated.

Abstract

 Serum antibodies IgM and IgG are elevated during COVID-19 to defend against viral attack. Atypical results such as negative and abnormally high antibody expression were frequently observed whereas the underlying molecular mechanisms are elusive. In our cohort of 144 COVID- 19 patients, 3.5% were both IgM and IgG negative whereas 29.2% remained only IgM negative. The remaining patients exhibited positive IgM and IgG expression, with 9.3% of them exhibiting over 20-fold higher titers of IgM than the others at their plateau. IgG titers in all of them were significantly boosted after vaccination in the second year. To investigate the underlying molecular mechanisms, we classed the patients into four groups with diverse serological patterns and analyzed their two-year clinical indicators. Additionally, we collected 111 serum samples for TMTpro-based longitudinal proteomic profiling and characterized 1494 proteins in total. We found that the continuously negative IgM and IgG expression during COVID-19 were associated with mild inflammatory reactions and high T cell responses. Low levels of serum IgD, inferior complement 1 activation of complement cascades, and insufficient cellular immune responses might collectively lead to compensatory serological responses, causing overexpression of IgM. Serum CD163 was positively correlated with antibody titers during seroconversion. This study

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

suggests that patients with negative serology still developed cellular immunity for viral defense,

and that high titers of IgM might not be favorable to COVID-19 recovery.

Introduction

 COVID-19 remains a threat to global health. The production of serum antibodies in the human body is a major defensive mechanism to neutralize SARS-CoV-2. Within them, IgM is initiated during the acute phase for early defense whereas IgG is secreted afterwards with a higher affinity for SARS-CoV-2 (1). Typically, COVID-19 patients underwent seroconversion (from 61 negative to positive) of IgM and IgG within 20 days (2). The IgM and IgG expression kept elevating before reaching the plateau, with IgG plateau titers higher and longer-lasting than IgM plateau titers (3). The timespans of seroreversion (from positive to negative) were around 3-6 64 months since disease onset for IgM $(4, 5)$ whereas hardly observed for IgG in one year (6). After vaccination, convalescent COVID-19 patients exhibited higher titers of IgM and IgG compared to healthy individuals (7). Several atypical serological patterns were documented in the literature. 3.2% to 6.9% of the COVID-19 patients remained low expression or seronegative for both IgM and IgG throughout the disease stage (1, 2). It has also been reported that less than 10% of the patients exhibited 10- to 20- fold higher antibody titers than the average values when reaching the plateau (1, 8). These unexpected serological patterns indicate heterogeneous host responses during COVID-19, with unclear molecular mechanisms. This study was designed to investigate the diverse expression patterns of IgM and IgG from a single-center cohort across two years of monitoring, and to explore the molecular evidence associated with atypical antibody expression via longitudinal proteomic profiling. **Experimental procedures**

Ethics and data governance approval

This study has been approved by the Ethical/Institutional Review Board of Westlake

University and Taizhou Hospital (approval notice: K20210218). The studies in this work abide by

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

81 the Declaration of Helsinki principles. Since archived specimens were used, informed consent

from the patients was waived by the boards. A flowchart of the study design is illustrated in Figure

1D.

Patient information

We included 144 COVID-19 patients who were admitted to Taizhou Public Health Medical

Center, Taizhou Hospital from January 17, 2020 to April 2, 2020. Within them, seventy-three

patients participated in the one-year follow-up between day 363-397 (IQR, 10) since disease onset

88 and fifty-eight patients participated in the two-year follow-up between day 728-763 (IQR, 7) since

disease onset.

Information about demographics, epidemiological history, clinical symptoms, laboratory

data, and hospitalization was collected through an electronic medical record system. All enrolled

patients were confirmed to be infected with SARS-CoV-2 by use of real-time reverse-transcriptase

polymerase-chain-reaction (RT-PCR) assay on the viral RNA extracted from nasopharyngeal or

sputum specimens, and the classification of their disease severity were based on Diagnostic and

Treatment Protocol for COVID-19 (Trial Version 5) issued by National Health Commission of the

People's Republic of China (9), unless otherwise mentioned. The onset date was defined as the

day when any symptoms were noticed by the patients.

Removal of identifying information

 All information that would allow the patient/study participant or their family, friends or neighbors to identify them (e.g., age, past medical history, etc.) has been removed. Patient IDs from hospital records have been replaced with identifiers that cannot reveal the identity of the

study subjects (e.g., R001, R002, etc.). The correspondence between identifiers and patient IDs

was not known to anyone outside the research group.

Laboratory characteristic tests

Nasopharyngeal or sputum specimens were collected to extract SARS-CoV-2 RNA, using a

- nucleic acid extractor (EX3600, Shanghai Zhijiang) and a virus nucleic acid extraction kit
- (P20200201, Shanghai Zhijiang). For nucleic acid detection, fluorescence quantitative PCR (ABI
- 7500, Thermo) coupled to a SARS- CoV-2 nucleic acid detection kit (P20200203, Shanghai

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

IgM and IgG when reaching the plateau. The cut-off value, as determined by the detection kit, was

136 10 AU/mL. A total of 47 patients had IgM titers below the cut-off value (IgM⁻), and three had IgG

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

137 titers below the cut-off value (IgG⁻). They were classified as seronegative for IgM and IgG,

respectively.

 Two patients had IgG titers above but close to the cut-off value. Specifically, the IgG plateau 140 was reached on the second and the $18th$ day after the symptoms' onset for patients R055 (16.11) AU/mL) and R101 (13.80 AU/mL), respectively. These were the "outliers" of the patients with IgG plateau titers above the cut-off value, accordingly to Tukey's test (Figure S2A). Clinicians 143 classified them as seronegative for IgG (IgG^-) . Similarly, nine patients with very high IgM expression were the "outliers" in the patients with IgM plateau titers above the cut-off value, accordingly to Tukey's test. Clinicians classed them as patients with abnormally high IgM 146 expression (IgM^{++}) . **Proteomic analysis** Serum samples were heated at 56 ℃ for over 60 min for inactivation. The sample preparation 149 procedures were conducted as described previously (10) with several modifications: $10 \mu L$ serum from each specimen of the sample cohort was extracted and loaded onto High Select Top14

Abundant Protein Depletion Mini Spin Columns (Thermo Scientific) for high abundance protein

depletion. Eluates were concentrated using Pierce™ Protein Concentrators PES, 3K MWCO

(Thermo Scientific), and denatured with 50 μL lysis buffer (6 M urea and 2 M thiourea in 0.1 M

triethylammonium bicarbonate, TEAB) at 31 ℃ for 30 min. The extracts were reduced with 10

mM tris (2-carboxyethyl) phosphine (Damas-beta) at 31℃ for 40 min and alkylated with 40 mM

iodoacetamide (Sigma) at 25℃ for 40 min in darkness. The samples were diluted with 0.1 M

TEAB buffer till the final concentration of urea was below 1.6 M, and trypsinized (Hualishi

Technology) in double-step with an enzyme-to-substrate ratio of 1:20 at 31℃, for 60 min and 120

min, respectively. Trypsinization was stopped by adding trifluoroacetic acid (Damas-beta) till the

final concentration of 1%, and digests were desalted with SOLAμ (Thermo Fisher Scientific),

following the manufacturer's instructions. Clean peptides were labeled with TMTpro 16plex label

reagent sets (Thermo Scientific) according to the labeling set (Figure S2). A pooled sample was

generated for labeling efficiency tests to ensure an incorporation ratio of over 95%. Afterward,

164 samples in the batch were combined and fractionated in previously described settings (10). 60

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 P roteomes behind diverse $CONID-10$

1200 system (Thermo Fisher Scientific) coupled with Q Exactive HF-X hybrid Quadrupole-

- Orbitrap (Thermo Fisher Scientific) was applied, and data-dependent acquisition (DDA) mode
- was used throughout the analysis. The parameters were as previously described (10), except a 60

min LC gradient was applied for each acquisition. The resultant data were analyzed with Proteome

Discoverer (Version 2.4.1.15). Protein database was a *Homo sapiens fasta* file downloaded from

UniprotKB on April 10, 2020 and other parameter settings were as previously described (10).

Statistical analysis

 For clinical data (demographic information and clinical indicators), p values were calculated by two-sided Wilcoxon rank-sum tests. For proteomics data, p values were calculated by one-way analysis of variance (ANOVA) in the comparisons of divergent antibody expression and by two- sided Student's t-test in other analyses. Benjamini & Hochberg correction was applied for p-value adjustment and labeled as *adjusted p*. Paired analyses were applied in comparing DEPs and in the 179 comparisons of clinical indicators from organ dysfunction. Signs: *, p < 0.05; **, p < 0.01; ***, p < 0.005; ****, p < 0.001. Spearman correlation coefficients were calculated for the correlation of clinical data and proteomic data. LOESS (locally weighted scatterplot smoothing) model was applied for fitting analysis. Unsupervised hierarchical clustering was applied to display the DEPs from dysregulated seroconversion.

 Categorical variables were described as frequency and percentage, and continuous variables were shown as mean and standard deviation or median and interquartile range (IQR) values as appropriate. To compare the continuous variables for data from different patient groups, an independent t-test was used when the data were normally distributed; otherwise, the Kruskal-188 Wallis H test was conducted. The categorical variables were compared using the χ^2 test and Fisher's exact test as appropriate. Statistical analyses were performed with R software (version 3.6.0).

Pathway analysis

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

- 192 Metascape (11), String (12), and Ingenuine Pathway Analysis were applied for pathway
- 193 enrichment in this study.
- 194
- 195 **Results**

196 **Negative and exceptionally high IgM and IgG expression in COVID-19**

197 We procured a cohort of 144 COVID-19 patients and used chemiluminescence

- 198 immunoassays (CLIAs) to assess their expression levels of IgM and IgG (Methods). 790, 72, and
- 199 58 CLIA tests were conducted during the first 10 weeks since disease onset (weeks 1-10), the one-
- 200 vear revisit $(R1)$, and the two-year revisit $(R2)$, respectively. 84.5% of the revisited patients
- 201 received vaccination between R1 and R2 (Table S1). Based on their plateau titers during weeks 1-
- 202 10, the antibodies' expression patterns were classified as follows: for negative results or very low
- 203 expression, \pm for positive results, and \pm for exceptionally high expression (Methods).
- 204 Accordingly, patients were classified into four groups: $IgG^{-}IgM^{T}(G^{-}M^{-}, N=5)$, $IgG^{+}IgM^{-}$
- 205 $(G^+M^-, N = 42)$, IgG⁺IgM⁺ (G⁺M⁺, N = 88), and IgG⁺IgM⁺⁺ (G⁺M⁺⁺, N = 9) (Figure S1A and
- 206 S1B).

207 We firstly assessed the IgM expression dynamics in the four groups. G^+M^+ and G^+M^{++} 208 patients underwent IgM seroconversion between weeks 1-2 (Figure 1A). However, the IgM titers 209 in the G⁺M⁺⁺ group were significantly higher since week 2 and were over 20-fold in expression 210 when reaching the plateau at week 4, compared to that in the G^+M^+ group. The IgM titers in the 211 G⁺M⁺⁺ group remained over ten-fold higher than the G⁺M⁺ group at weeks 7-10. Comparatively, 212 none of the patients in the G⁺M⁻ or the G⁻M⁻ group underwent IgM seroconversion during 213 weeks 1-10. The overall IgM titers of the four groups had a significant decrease from weeks 1-10 214 to R1, which were further decreased at R2. Only 13.9% ($N = 10$) and 5.2% ($N = 3$) of the revisited 215 patients were IgM seropositive at R1 and R2, respectively. The statistical differences in IgM titers 216 between the G⁺M⁻ and the G⁺M⁺ groups persisted at R1 and R2, suggesting a long-term effect of 217 COVID-19.

218 As for the IgG expression dynamics, all the groups except the $G-M^-$ group underwent 219 seroconversion at weeks 1-2 and reached the plateau at week 3 (Figure 1B). Their IgG titers

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

their longitudinal proteomic signatures during weeks 1-10 (Figure 3A). A total of 1494 proteins

- were characterized using TMTpro 16plex technology (Figure S2B and Table S3). The median
- value of the protein coefficient of variation (CV) for the pooled samples is 0.189 (Figure S2C),

indicating high quality of our data.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

- In summary, the proteomic differences in the four groups were the most prominent during
- weeks 1-2, which were associated with complement cascades. The main host response differences

during the late stage of COVID-19 relate to the leukocyte activities.

Correlation between serum proteomes and clinical indicators

Beyond the functional analyses, we explored the correlation between the DEPs and the

antibody titers during weeks 1-4 since disease onset. Five and four DEPs were significantly

correlated with IgM and IgG expression titers (absolute value of Spearman correlation coefficient

is over 0.5), respectively (Figure 4A). Within them, TIMP1, ICAM1, CD163, NOTCH2, and

HLD-DRB1 are associated with inflammatory response, corroborating the important role of

inflammation in serology. CD163, a marker for monocytic macrophages (23), is the most

correlated protein with IgG among these regulators. As exemplified in Figure 4B, the expression

of serum CD163 was positively correlated with antibody titers and was significantly higher than

343 the other groups in the $G⁺M⁺$ group throughout weeks 1-4, suggestive of their more activated

macrophage polarization during COVID-19 (24).

We also assessed the correlation between clinical indicators and DEPs during weeks 1-10

(Figure 4C). HDL-C was significantly correlated with MERTK (Figure 4D), a transmembrane

kinase that contributes to the B lymphocyte activation (25). TG was positively correlated with

serum CD34 (Figure 4E), a human hematopoietic stem cell marker that also has a role in

facilitating inflammatory cell trafficking. These evidences further suggested lipid involvement in

the immunological activities during COVID-19.

A putative working model for diverse serology in COVID-19

 Based on our data, we propose a putative working model regarding the diverse COVID-19 serology (Figure 4F). Complement cascade is initiated upon disease onset, mediating the secretion of cytokines such as IL-6 and IL-10. This process could trigger macrophage polarization, as

- exemplified by the upregulation of CD163, which would further modulate local inflammation. The
- subsequently activated neutrophils and T lymphocytes could initiate B cell differentiation, leading

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

entry, which further induces the expression of inflammatory factors (27).

Our observation that a list of CD molecules (CD3, CD4, CD8, and CD19) were highly

- 383 expressed in the $G-M^-$ patients whereas decreased in the $G+M^{++}$ patients during COVID-19
- suggested their differentially regulated lymphocytes to confront viral attacks. The low expression
- of T and B lymphocyte markers, namely lymphopenia, has been established as a severity hallmark

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

patient cohort was possibly subject to demographic and experimental biases. Also, the sampling

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

- time points failed to cover the seroreversion stages for IgG. Furthermore, as the major purpose is
- to profile host responses associated with diverse serology patterns, we didn't validate specific
- markers in this study.
-

Data availability

- Patient information and serology data are available in the supplementary material. The
- proteomic raw data are deposited in ProteomeXchange Consortium
- (https://www.iprox.cn/page/PSV023.html;?url=1660551727880pH06, password: VcQ7).
-

Acknowledgments

- This work was supported by grants from National Key R&D Program of China
- (2021YFA1301602, 2020YFE0202200), National Natural Science Foundation of China
- (81972492, 21904107, 82072333), Zhejiang Provincial Natural Science Foundation for
- Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society Advancement
- Program (20190101A04), Medical Science and Technology Project of Zhejiang Province
- (2021KY394), Westlake Education Foundation, and Scientific Research Foundation of Taizhou
- Enze Medical Center (Group) (21EZZX01). We thank Westlake University Supercomputer Center
- for assistance in data storage and computation.
-

Author Contributions

- Y.Z., B.S., and T.G. designed the project, Y.Z., J.W., K.Z., D.W., and G.Z. collected the samples,
- X.L., J.W., K.Z., J.L, S.C., M.L., J.P., J.X., H.Z., and G.Z. organized the sample information, X.L.,
- S.L., and X.Y. prepared the samples, X.L., M.L., Y.S., Y.X., and Q.Z. performed the data analysis,
- X.L., Y.X., and Q.Z. designed the figures, X.L. and R.S. wrote the manuscript, Y.Z., B.S., Y.Z.,
- and T.G. supervised the project.
-

Competing Interests statement

Q.Z. and X.Y. are employees of Westlake Omics Inc. Y.Z. and T.G. are shareholders of Westlake

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

Omics Inc. The remaining authors declare no competing interests.

Supplementary data

This article contains supplemental material Table S1-S3 and Figure S1-S2.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

References

- 1. Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., Liao, P., Qiu, J. F., Lin, Y.,
- Cai, X. F., Wang, D. Q., Hu, Y., Ren, J. H., Tang, N., Xu, Y. Y., Yu, L. H., Mo, Z., Gong, F., Zhang, X.
- L., Tian, W. G., Hu, L., Zhang, X. X., Xiang, J. L., Du, H. X., Liu, H. W., Lang, C. H., Luo, X. H., Wu, S.
- B., Cui, X. P., Zhou, Z., Zhu, M. M., Wang, J., Xue, C. J., Li, X. F., Wang, L., Li, Z. J., Wang, K., Niu, C.
- C., Yang, Q. J., Tang, X. J., Zhang, Y., Liu, X. M., Li, J. J., Zhang, D. C., Zhang, F., Liu, P., Yuan, J., Li,
- Q., Hu, J. L., Chen, J., and Huang, A. L. (2020) Antibody responses to SARS-CoV-2 in patients
- with COVID-19. Nat Med 26, 845-848
- 2. Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., Qian, S.,
- Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., Ge, S., Liu, L., Zhang, J.,
- Xia, N., and Zhang, Z. (2020) Antibody Responses to SARS-CoV-2 in Patients With Novel
- Coronavirus Disease 2019. Clin Infect Dis 71, 2027-2034
- 3. Jin, Y., Wang, M., Zuo, Z., Fan, C., Ye, F., Cai, Z., Wang, Y., Cui, H., Pan, K., and Xu, A. (2020)
- Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.
- International Journal of Infectious Diseases 94, 49-52
- 4. Iyer, A. S., Jones, F. K., Nodoushani, A., Kelly, M., Becker, M., Slater, D., Mills, R., Teng, E.,
- Kamruzzaman, M., Garcia-Beltran, W. F., Astudillo, M., Yang, D., Miller, T. E., Oliver, E., Fischinger,
- S., Atyeo, C., Iafrate, A. J., Calderwood, S. B., Lauer, S. A., Yu, J., Li, Z., Feldman, J., Hauser, B. M.,
- Caradonna, T. M., Branda, J. A., Turbett, S. E., LaRocque, R. C., Mellon, G., Barouch, D. H.,
- Schmidt, A. G., Azman, A. S., Alter, G., Ryan, E. T., Harris, J. B., and Charles, R. C. (2020)
- Persistence and decay of human antibody responses to the receptor binding domain of SARS-
- 469 CoV-2 spike protein in COVID-19 patients. Sci Immunol 5, eabe0367
- 5. den Hartog, G., Vos, E. R. A., van den Hoogen, L. L., van Boven, M., Schepp, R. M., Smits, G.,
- van Vliet, J., Woudstra, L., Wijmenga-Monsuur, A. J., van Hagen, C. C. E., Sanders, E. A. M., de
- Melker, H. E., van der Klis, F. R. M., and van Binnendijk, R. S. (2021) Persistence of Antibodies to
- Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide
- 474 Prospective Study. Clin Infect Dis 73, 2155-2162
- 6. Masiá, M., Fernández-González, M., Telenti, G., Agulló, V., García, J. A., Padilla, S., García-

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Abellán, J., Galiana, A., Gonzalo-Jiménez, N., and Gutiérrez, F. (2021) Durable antibody response
- 477 one year after hospitalization for COVID-19: A longitudinal cohort study. *J Autoimmun* 123,
- 102703-102703
- 7. Ali, H., Alahmad, B., Al-Shammari, A. A., Alterki, A., Hammad, M., Cherian, P., Alkhairi, I.,
- Sindhu, S., Thanaraj, T. A., Mohammad, A., Alghanim, G., Deverajan, S., Ahmad, R., El-Shazly, S.,
- Dashti, A. A., Shehab, M., Al-Sabah, S., Alkandari, A., Abubaker, J., Abu-Farha, M., and Al-Mulla,
- 482 F. (2021) Previous COVID-19 Infection and Antibody Levels After Vaccination. Frontiers in public
- health 9, 778243-778243
- 8. Geyer, P. E., Arend, F. M., Doll, S., Louiset, M.-L., Virreira Winter, S., Müller-Reif, J. B., Torun,
- F. M., Weigand, M., Eichhorn, P., Bruegel, M., Strauss, M. T., Holdt, L. M., Mann, M., and Teupser,
- D. (2021) High-resolution serum proteome trajectories in COVID-19 reveal patient-specific
- 487 seroconversion. EMBO Mol Med 13, e14167-e14167
- 9. Suhre, K., McCarthy, M. I., and Schwenk, J. M. (2020) Genetics meets proteomics:
- 489 perspectives for large population-based studies. Nat Rev Genet
- 10. Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., Ge, W.,
- Liu, W., Liang, S., Chen, H., Zhang, Y., Li, J., Xu, J., He, Z., Chen, B., Wang, J., Yan, H., Zheng, Y.,
- Wang, D., Zhu, J., Kong, Z., Kang, Z., Liang, X., Ding, X., Ruan, G., Xiang, N., Cai, X., Gao, H., Li, L.,
- Li, S., Xiao, Q., Lu, T., Zhu, Y., Liu, H., Chen, H., and Guo, T. (2020) Proteomic and Metabolomic
- 494 Characterization of COVID-19 Patient Sera. Cell 182, 59-72.e15
- 11. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C.,
- and Chanda, S. K. (2019) Metascape provides a biologist-oriented resource for the analysis of
- 497 systems-level datasets. Nat Commun 10, 1523
- 12. Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M.,
- Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., and Mering, C. V. (2019) STRING v11:
- protein-protein association networks with increased coverage, supporting functional discovery in
- 501 genome-wide experimental datasets. Nucleic Acids Res 47, D607-d613
- 13. Aziz, M., Fatima, R., Lee-Smith, W., and Assaly, R. (2020) The association of low serum
- 503 albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care 24, 255

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 14. Luo, Y., Xue, Y., Mao, L., Yuan, X., Lin, Q., Tang, G., Song, H., Wang, F., and Sun, Z. (2020)
- 505 Prealbumin as a Predictor of Prognosis in Patients With Coronavirus Disease 2019. Front Med (Lausanne) 7, 374
- 15. Akbari, H., Tabrizi, R., Lankarani, K. B., Aria, H., Vakili, S., Asadian, F., Noroozi, S., Keshavarz,
- P., and Faramarz, S. (2020) The role of cytokine profile and lymphocyte subsets in the severity of
- 509 coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Life Sci 258,
- 118167
- 16. Zhao, Y., Nie, H. X., Hu, K., Wu, X. J., Zhang, Y. T., Wang, M. M., Wang, T., Zheng, Z. S., Li, X.
- C., and Zeng, S. L. (2020) Abnormal immunity of non-survivors with COVID-19: predictors for
- 513 mortality. Infect Dis Poverty 9, 108
- 17. Masana, L., Correig, E., Ibarretxe, D., Anoro, E., Arroyo, J. A., Jericó, C., Guerrero, C., Miret,
- M., Näf, S., Pardo, A., Perea, V., Pérez-Bernalte, R., Plana, N., Ramírez-Montesinos, R., Royuela,
- M., Soler, C., Urquizu-Padilla, M., Zamora, A., and Pedro-Botet, J. (2021) Low HDL and high
- 517 triglycerides predict COVID-19 severity. Sci Rep 11, 7217
- 18. D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., Francis, R. O., Hudson, K. E.,
- Zimring, J. C., Hod, E. A., Spitalnik, S. L., and Hansen, K. C. (2020) Serum Proteomics in COVID-19
- 520 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level. Journal of
- proteome research 19, 4417-4427
- 19. Schneider, W. M., Luna, J. M., Hoffmann, H. H., Sánchez-Rivera, F. J., Leal, A. A., Ashbrook, A.
- W., Le Pen, J., Ricardo-Lax, I., Michailidis, E., Peace, A., Stenzel, A. F., Lowe, S. W., MacDonald, M.
- R., Rice, C. M., and Poirier, J. T. (2021) Genome-Scale Identification of SARS-CoV-2 and Pan-
- 525 coronavirus Host Factor Networks. Cell 184, 120-132.e114
- 20. Lutz, C., Ledermann, B., Kosco-Vilbois, M. H., Ochsenbein, A. F., Zinkernagel, R. M., Köhler,
- 527 G., and Brombacher, F. (1998) IgD can largely substitute for loss of IgM function in B cells. Nature
- 393, 797-801
- 21. Holleboom, A. G., Vergeer, M., Hovingh, G. K., Kastelein, J. J., and Kuivenhoven, J. A. (2008)
- 530 The value of HDL genetics. Current opinion in lipidology 19, 385-394
- 22. Chakraborty, S., Gonzalez, J., Edwards, K., Mallajosyula, V., Buzzanco, A. S., Sherwood, R.,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Buffone, C., Kathale, N., Providenza, S., Xie, M. M., Andrews, J. R., Blish, C. A., Singh, U., Dugan, H.,
- Wilson, P. C., Pham, T. D., Boyd, S. D., Nadeau, K. C., Pinsky, B. A., Zhang, S., Memoli, M. J.,
- Taubenberger, J. K., Morales, T., Schapiro, J. M., Tan, G. S., Jagannathan, P., and Wang, T. T.
- 535 (2021) Proinflammatory IgG Fc structures in patients with severe COVID-19. Nature immunology
- 22, 67-73
- 23. Etzerodt, A., and Moestrup, S. K. (2013) CD163 and inflammation: biological, diagnostic, and 538 therapeutic aspects. Antioxid Redox Signal 18, 2352-2363
- 24. Boumaza, A., Gay, L., Mezouar, S., Bestion, E., Diallo, A. B., Michel, M., Desnues, B., Raoult,
- D., La Scola, B., Halfon, P., Vitte, J., Olive, D., and Mege, J. L. (2021) Monocytes and Macrophages,
- Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease
- 2019 Immunoparalysis. J Infect Dis 224, 395-406
- 25. Shao, W. H., Zhen, Y., Finkelman, F. D., and Cohen, P. L. (2014) The Mertk receptor tyrosine
- 544 kinase promotes T-B interaction stimulated by IgD B-cell receptor cross-linking. *J Autoimmun* 53, 78-84
- 26. Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., Hauser,
- B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., Murali, M. R., Alter, G., Charles, R. C., Dighe,
- A., Branda, J. A., Lennerz, J. K., Lingwood, D., Schmidt, A. G., Iafrate, A. J., and Balazs, A. B. (2021)
- 549 COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184, 476-488.e411
- 27. Wen, J., Cheng, Y., Ling, R., Dai, Y., Huang, B., Huang, W., Zhang, S., and Jiang, Y. (2020)
- 551 Antibody-dependent enhancement of coronavirus. Int J Infect Dis 100, 483-489
- 28. Liu, K., Yang, T., Peng, X. F., Lv, S. M., Ye, X. L., Zhao, T. S., Li, J. C., Shao, Z. J., Lu, Q. B., Li, J.
- Y., and Liu, W. (2021) A systematic meta-analysis of immune signatures in patients with COVID-
- 19. Rev Med Virol 31, e2195
- 29. He, R., Lu, Z., Zhang, L., Fan, T., Xiong, R., Shen, X., Feng, H., Meng, H., Lin, W., Jiang, W., and
- 556 Geng, Q. (2020) The clinical course and its correlated immune status in COVID-19 pneumonia. *J*
- Clin Virol 127, 104361
- 30. Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., Li,
- X., Sun, Y., Li, L., Xu, L., Li, Y., Yang, M., Xue, Z., Liang, S., Ding, X., Yuan, C., Peng, L., Liu, W., Yi, X.,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2022.08.21.22278967;](https://doi.org/10.1101/2022.08.21.22278967) this version posted August 22, 2022. The copyright holder for this

Proteomes behind diverse COVID-19 serology

- Lyu, M., Xiao, G., Xu, X., Ge, W., He, J., Fan, J., Wu, J., Luo, M., Chang, X., Pan, H., Cai, X., Zhou, J.,
- Yu, J., Gao, H., Xie, M., Wang, S., Ruan, G., Chen, H., Su, H., Mei, H., Luo, D., Zhao, D., Xu, F., Li, Y.,
- Zhu, Y., Xia, J., Hu, Y., and Guo, T. (2021) Multi-organ proteomic landscape of COVID-19
- 563 autopsies. Cell 184, 775-791.e714
- 31. Wendisch, D., Dietrich, O., Mari, T., von Stillfried, S., Ibarra, I. L., Mittermaier, M., Mache, C.,
- Chua, R. L., Knoll, R., Timm, S., Brumhard, S., Krammer, T., Zauber, H., Hiller, A. L., Pascual-
- Reguant, A., Mothes, R., Bülow, R. D., Schulze, J., Leipold, A. M., Djudjaj, S., Erhard, F., Geffers, R.,
- Pott, F., Kazmierski, J., Radke, J., Pergantis, P., Baßler, K., Conrad, C., Aschenbrenner, A. C.,
- Sawitzki, B., Landthaler, M., Wyler, E., Horst, D., Hippenstiel, S., Hocke, A., Heppner, F. L., Uhrig,
- A., Garcia, C., Machleidt, F., Herold, S., Elezkurtaj, S., Thibeault, C., Witzenrath, M., Cochain, C.,
- Suttorp, N., Drosten, C., Goffinet, C., Kurth, F., Schultze, J. L., Radbruch, H., Ochs, M., Eils, R.,
- Müller-Redetzky, H., Hauser, A. E., Luecken, M. D., Theis, F. J., Conrad, C., Wolff, T., Boor, P.,
- Selbach, M., Saliba, A. E., and Sander, L. E. (2021) SARS-CoV-2 infection triggers profibrotic
- 573 macrophage responses and lung fibrosis. Cell 184, 6243-6261.e6227
- 32. Li, Y., Zhang, Y., Lu, R., Dai, M., Shen, M., Zhang, J., Cui, Y., Liu, B., Lin, F., Chen, L., Han, D.,
- Fan, Y., Zeng, Y., Li, W., Li, S., Chen, X., Li, H., and Pan, P. (2021) Lipid metabolism changes in
- 576 patients with severe COVID-19. Clin Chim Acta 517, 66-73
- 33. Zhang, J., Lin, H., Ye, B., Zhao, M., Zhan, J., Dong, S., Guo, Y., Zhao, Y., Li, M., Liu, S., Zhang,
- H., Xiao, W., Guo, Y., Yue, C., Zhang, D., Yang, M., Zhang, J., Quan, C., Shi, W., Liu, X., Liu, P.,
- Jiang, Y., Wu, G., Gao, G. F., and Liu, W. J. (2021) One-year sustained cellular and humoral
- 580 immunities of COVID-19 convalescents. Clin Infect Dis
- 34. Favresse, J., Gillot, C., Di Chiaro, L., Eucher, C., Elsen, M., Van Eeckhoudt, S., David, C.,
- Morimont, L., Dogné, J. M., and Douxfils, J. (2021) Neutralizing Antibodies in COVID-19 Patients
- 583 and Vaccine Recipients after Two Doses of BNT162b2. Viruses 13
-

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Proteomes behind diverse COVID-19 serology

Figure legends

- monitoring of SARS-CoV-2-specific IgM and IgG expression in COVID-19 patients. The y-axis
- denotes log-transformed antibody titers. The statistical significance was calculated within and
- across each timepoint. C) Comparison of IgG expression before and after vaccination. D) Study
- design for clinical and proteomic analyses of diverse serology in COVID-19.
-
- **Figure 2 Clinical characteristics of patients with diverse serology.** A) Distributions of severe
- cases in the four groups. B) Expression of nine selected clinical indicators on admission. C) Two-
- year temporal expression of ten selected clinical indicators.
-

Figure 3 Longitudinal serum proteomics of 16 characteristic patients with diverse serology.

- A) Temporal serum sampling for the 16 characteristic patients. B) Heatmap and functional
- annotation of 77 DEPs across 10 weeks of proteomic profiling. C) PCA of serum samples
- stratified by the DEPs at weeks 1-2 and weeks 4-10, respectively. The ellipses are shown at a
- confidence interval of 95%. D) Interaction network of selected DEPs at weeks 1-2. E) Relative
- expression of DEPs C1QB, C1QC, and IgD at weeks 1-2. F) Interaction network of selected DEPs

at weeks 7-10. G) Relative expression of DEPs VNN1 and FCGR3A at weeks 7-10.

- DEPs that were correlated with antibody expression during weeks 1-4 (absolute values of
- spearman correlation > 0.5). B) Temporal expression of CD163 during weeks 1- 4. C)
- Correlations of clinical indicators with DEPs during weeks 1-10 (absolute values of spearman
- correlation > 0.65). D-E) Scatterplots of two sets of correlations: MERTK~HDL-C and
- CD34~TG, respectively. F) A putative working model for the host responses behind diverse
- COVID-19 serology.

Figure 1

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

C

Figure 2

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.08.21.22278967;](https://doi.org/10.1101/2022.08.21.22278967) this version posted August 22, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

Macrophage differentiation

G+M++ **HELLE**

Neutrophil

B cell Plasma cell